SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma

International Journal of Cancer

Volumn 132, Issue 2, 2013, Pages 459-471

  Iwahori, Kota ^a,b   Serada, Satoshi ^a   Fujimoto, Minoru ^a   Ripley, Barry ^b   Nomura, Shintaro ^c   Mizuguchi, Hiroyuki ^a   Shimada, Kazuki ^a,b   Takahashi, Tsuyoshi ^b   Kawase, Ichiro ^d   Kishimoto, Tadamitsu ^b   Naka, Tetsuji ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

^d OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

gene therapy; malignant pleural mesothelioma; NF B; SOCS 1; STAT3

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEMETREXED; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; GLUTAMATES; GUANINE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; MESOTHELIOMA; MICE; MICE, INBRED ICR; MICE, NUDE; NEOPLASM INVASIVENESS; NF-KAPPA B; PLEURAL NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869502945     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27611     Document Type: Article

References (50)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
2. Kelly RJ, Sharon E, Hassan R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 2011;73:256-63.
3. Pelucchi C, Malvezzi M, La Vecchia C, et al. The mesothelioma epidemic in Western Europe: an update. Br J Cancer 2004;90:1022-4.
4. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9:206-17.
5. Leithner K, Leithner A, Clar H, et al. Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40. Orphanet J Rare Dis 2006;1:44.
6. Murayama T, Takahashi K, Natori Y, et al. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 2006;49:1-7.
7. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
8. Bollrath J, Greten FR. IKK/NF-jB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009;10:1314-19.
9. Janssen YM, Barchowsky A, Treadwell M, et al. Asbestos induces nuclear factor kappa B (NFjB) DNA-binding activity and NF-kappa B-dependent gene expression in tracheal epithelial cells. Proc Natl Acad Sci USA 1995;92: 8458-62.
10. Luster MI, Simeonova PP. Asbestos induces inflammatory cytokines in the lung through redox sensitive transcription factors. Toxicol Lett 1998;102/103:271-5.
11. Simeonova PP, Luster MI. Asbestos induction of nuclear transcription factors and interleukin 8 gene regulation. Am J Respir Cell Mol Biol 1996; 15:787-95.
12. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-4.
13. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-9.
14. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21.
15. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-jB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003;12:1413-26.
16. Narazaki M, Fujimoto M, Matsumoto T, et al. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci USA 1998;95:13130-4.
17. Yasukawa H, Misawa H, Sakamoto H, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999;18:1309-20.
18. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28: 29-35.
19. Nagai H, Kim YS, Konishi N, et al. Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Lett 2002;186:59-65.
20. Fukushima N, Sato N, Sahin F, et al. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 2003;89:338-43.
21. Galm O, Yoshikawa H, Esteller M, et al. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003;101:2784-8.
22. Oshimo Y, Kuraoka K, Nakayama H, et al. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 2004;112:1003-9.
23. Sterman DH, Recio A, Carroll RG, et al. A phase I clinical trial of single-dose intrapleural IFN-b gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007;13:4456-66.
24. Sterman DH, Recio A, Vachani A, et al. Longterm follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005;11: 7444-53.
25. Yamana J, Yamamura M, Okamoto A, et al. Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 2004;6:R567-R577.
26. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999;10: 2013-17.
27. Sakurai H, Tashiro K, Kawabata K, et al. Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vector-induced innate immune responses. J Immunol 2008;180: 4931-8.
28. Maizel JV, Jr, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968;36:115-25.
29. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007;13:5995-6000.
30. Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000-5.
31. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010;42:210-13.
32. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-jB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1: 661-71.
33. Zhong H, May MJ, Jimi E, et al. The phosphorylation status of nuclear NF-jB determines its association with CBP/p300 or HDAC-1. Mol Cell 2002;9:625-36.
34. Nakagawa R, Naka T, Tsutsui H, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002;17:677-87.
35. Hayden MS, Ghosh S. Signaling to NF-jB. Genes Dev 2004;18:2195-224.
36. Campbell KJ, Witty JM, Rocha S, et al. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-jB transactivation. Cancer Res 2006;66:929-35.
37. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;3:1533-42.
38. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-42.
39. Haga S, Terui K, Zhang HQ, et al. Stat3 protects against Fas-induced liver injury by redoxdependent and -independent mechanisms. J Clin Invest 2003;112:989-98.
40. Stehlik C, de Martin R, Kumabashiri I, et al. Nuclear factor (NF)-jB-regulated Xchromosome- linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998;188: 211-16.
41. Wen LP, Fahrni JA, Troie S, et al. Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem 1997;272:26056-61.
42. Bachelder RE, Ribick MJ, Marchetti A, et al. p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 1999;147:1063-72.
43. Liu E, Cote JF, Vuori K. Negative regulation of FAK signaling by SOCS proteins. EMBO J 2003; 22:5036-46.
44. Calabrese V, Mallette FA, Deschenes-Simard X, et al. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 2009;36:754-67.
45. Souma Y, Nishida T, Serada S, et al. Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells. Int J Cancer, in press.
46. Kimura A, Naka T, Nagata S, et al. SOCS-1 suppresses TNF-a-induced apoptosis through the regulation of Jak activation. Int Immunol 2004;16: 991-9.
47. Scutti JA, Matsuo AL, Pereira FV, et al. Role of SOCS-1 gene on melanoma cell growth and tumor development. Transl Oncol 2011;4:101-9.
48. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
49. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
50. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 2010;101:1-6.